Therapeutical effects


The high frequencies: their therapeutical effects

Are high frequencies really that effective?

Our devices are a technological and therapeutic innovation especially in the field of physical therapy and physiotherapy (Pronexibus Plus®) and in the field of difficult skin lesions (Rinovacell®). But why are they innovative? And who certified the results?

The innovation lies in the use of specific radio frequencies: the controlled high frequencies. Other types of radio frequencies are commonly used in the medical field: tecar-therapy, for example, uses lower frequencies – in the range of medium frequencies – which have a different biological behavior.

So the high frequencies are a complete innovation and a new alternative compared to electromedical devices already on the market, also can boast of the exceptional beneficial effects for the very short time in which they develop:

  • Antalgic effect
  • Anti-inflammatory effect
  • Myorelaxant effect
  • Anti-edema effect
  • Proregenerative effect

But, who certified the results?

Therapeutical effects: painkiller ability and myorelaxation.

ProNexibus Plus®: Padova and Verona Universities.

I.S.MuL.T Congress

Summary of the trial on the ProNexibus Plus® trial developed by the group of Dr Picelli.

Two independent studies have been developed thanks to the interest of the Universities of Padua and Verona.

The research group of the Prof. Masiero, through a protocol with 10 sessions of just 10-15 minutes each, found that the Pronexibus Plus® significantly reduces pain in the setting of several musculoskeletal problems (e.g. osteoarthritis of the knee, neck pain, tendinopathies of the shoulder and of the elbow); moreover they have highlighted that the patients have been facilitated in the resumption of both their work and social-related activities.

Independently, Dr Picelli’s research group used Pronexibus Plus® to relieve pain from muscle spasticity in patients who developed a stroke in the past. In this case the therapy was effective in reducing muscle spasticity even in the follow up.




Therapeutical effects: proregenerative, anti-edema and anti-inflammatory.

Rinovacell®: Salerno University – RITRALED study.

Effetti benefici_ENG 1

Summary of the results of the RITRALED trial on the Rinovacell®.


The Rinovacell® was studied at the University of Salerno, by the team of Dr Bruno Luigi Farina. The results were surprising: in patients with chronic diabetic foot ulcers, that is, skin lesions that have remained open for over 6 months, the treatment with Rinovacell® allowed the closure of the ulcer. Clinically, the researchers noted a very important reduction of the edema of the foot and a very important anti-inflammatory and antalgic effect: after 1 or 2 therapy sessions the patient’s foot was already deflated and no longer erythematous; after 10 sessions the ulcer has closed in almost all cases.





Safety and future directions.

In all the studies carried out with the devices FocusMed® there were no side effects, the therapy was well tolerated by the patients and, indeed, according to many researchers, many patients were impressed by the benefits that the therapy gave them.


The University of Verona, amazed by the experimental results obtained, wanted to continue research on our devices in the hope of finding new solutions to increasingly debilitating diseases.

The Rinovacell®, on the other hand, will be used in a double-blind research project in collaboration with the polyclinic of Abano to deepen the effects of the device in the context of diabetic foot pathology.


If you have come this far and want to learn more about how and why the beneficial effects develop on our body click here.



Masiero, S. et al. Short-wave diathermy in the clinical management of musculoskeletal disorders: a pilot observational study. Int. J. Biometeorol. (2019) doi:10.1007/s00484-019-01806-x.

ProNexibus Plus® for patients with spastc equinovarous foot lesion, University of Verona, Dr Picelli, 29-30th November 2019, 9° Congress I.S.Mu.L.T.

The RITRALED Study: Rinovacell in the treatmento of diabetic trophic lesions, University of Salerno, Dr Bruno Luigi Farina, 19th-21st September 2013, XII AIUC National Congress.


Contact us

In our opinion, your privacy is fundamental: your personal data, needed to complete the form, are going to be treated with the most recent European General Data Protection Regulation (GDPR), which is accessible here. The data will be stored only for the shortest time needed to satisfy your inquiry. We appreciate your comprehension.

Privacy approval

5 + 10 =



Clicca sull'icona per inviare un messaggio con WhatsApp, oppure inviaci una mail cliccando quì.


Click to send a message with WhatsApp, or send us an email by clicking here .

× Help